ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Peregrine Pharmaceuticals, Inc. 

14272 Franklin Avenue, Suite 100

Tustin  California  92780  U.S.A.
Phone: 714-508-6000 Fax: 714-838-5817


SEARCH JOBS




Collaborations

AVANIR Pharmaceuticals 





 Company News
Phase II Clinical Data Of Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab In Combination With Sorafenib Presented At American Society of Clinical Oncology Gastrointestinal Cancers Symposium 1/16/2015 10:33:57 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Reports Second Quarter Fiscal Year 2015 Financial Results And Recent Developments 12/12/2014 11:11:04 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 12/11/2014 8:17:00 AM
Peregrine Pharmaceuticals, Inc. (PPHM) To Report Second Quarter Fiscal 2015 Financial Results After Market On December 10, 2014 12/5/2014 3:28:26 PM
Phase II Clinical Data Presented At SITC Annual Meeting Support Immunotherapeutic Mechanism Of Action Of Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab In Liver Cancer 11/10/2014 10:53:32 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Release: Data To Be Presented At The SITC Annual Meeting Support Synergy Of PS-Targeting And Anti-CTLA-4 Immunotherapies To Enhance Anti-Tumor Treatments In Melanoma 11/10/2014 10:47:00 AM
Promising Data Presented At The Chicago Multidisciplinary Symposium On Thoracic Oncology From An Investigator-Sponsored Trial Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab In Combination With Pemetrexed And Carboplatin In Front-Line Non-Small Cell Lung Cancer 10/30/2014 11:11:54 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Release: Data To Be Published In The Journal Of Immunology Research Support Phosphatidylserine (PS) As A Potential Target In Ebola Infection 10/15/2014 11:21:18 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Release: Data To Be Presented At CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance The Anti-Tumor Activity Of Immune Checkpoint Inhibitors By Decreasing Levels Of Myeloid Derived Suppressor Cells (MDSC) In The Tumor Microenvironment 10/6/2014 11:01:06 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 9/10/2014 12:00:46 PM
12345678910...